GleamWall
中文EN

HEPA Hepion Pharmaceuticals, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 1583771 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY20.4%
TTM EPS YoY98.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-166.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets180.2%
Debt / equity—
Current ratio4.43x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio-120.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$445,512$11.85M
SG&A expense$3.32M$7.50M
Operating income-$4.16M-$19.35M
Pretax income-$8.28M-$16.16M
Income tax—-$2.97M
Net income-$8.28M-$13.19M
EBITDA—-$19.32M
EPS (basic)-0.88-107.35
EPS (diluted)-0.88-107.35
Weighted avg. shares (diluted)9.41M122,894
Balance sheet
Cash & equivalents$1.83M$406,408
Current assets$3.07M$1.61M
Total assets$3.07M$1.61M
Current liabilities$299,383$3.14M
Total liabilities$402,405$3.48M
Shareholders' equity$2.67M-$1.86M
Shares outstanding11.62M139,168
Cash flow statement
Operating cash flow-$3.27M-$18.22M
Investing cash flow-$132,117-$600,000
Financing cash flow$4.83M$4.35M
Depreciation & amortization—$30,758
Stock-based compensation$20,783$791,645

Free plan shows the latest 2 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.